Facebook      Twitter

blank

blank

ONLINE LEARNING CENTER
 

HPV-Related Diseases in HIV-Infected Individuals (18HH11)

Debra Chew, MD, MPH, Clinical Assistant Professor, Division of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School, Lisa Dever, MD, Vice Chair for Faculty Development in the Department of Medicine, Clinical Chief of Infectious Diseases and the Director of the Infectious Disease Fellows, Rutgers New Jersey Medical School, and Shobha Swaminathan, MD, Assistant Professor, Division of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School

Home | Page 1 | Page 2 | Page 3 | Page 4
References | Post-Test
 
 
 

REFERENCES

  1. Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MD et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013; 40(3):187-193.
  2. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113(10suppl):3036-3046.
  3. Jemal A, Simard EP, Dorell C, et al. Annual report to the nation on the future” since it is implied].status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013;105:175-201.
  4. Kurdgelashvili G, Dores GM, Srour SA, Chaturvedi AK, Huycke MM, Devesa SS. Incidence of potentially human papillomavirus-related neoplasms in the United States, 1978to 2007. Cancer 2013;119:2291-2299.
  5. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92(18):1500-1510.
  6. Clifford GM, Polesel J, Rickenbach M et al. Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005;97:425-432.
  7. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirusassociated cancers among persons with AIDS. J Natl Cancer Inst 2009;101:1120-1130.
  8. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1.
  9. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428.
  10. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rosseau M-C, Desy M, Rohan TE. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis.1999;180(5):1415-1423.
  11. Molan M, van den Brule A, Plummer M, Weiderpass, E, Posso H, Arslan A et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5 year follow-up study. Am J Epidemiol 2003;158:486-494.
  12. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6,11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 2009;200:1059-1067.
  13. Chin-Hong PV, Vittinghoff E, Cranston RD, Buchbinder S, Cohen D, Colfax G et al. Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis 2004;190:2070-2076.
  14. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012;307:693.
  15. Kreimer AR, Pierce Campbell CM, Lin HY et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet 2013;382:877.
  16. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.
  17. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012;30 Suppl5:F55-70.
  18. Konopnicki D, DeWit S, Clumeck N. HPV and HIV coinfection: a complex interaction resulting in epidemiological, clinical and therapeutic implications. Future Virology. 2013;8(9):903-915.
  19. Kurman R, Solomon D. The Bethedsda system for reporting cervical/vaginal cytologic diagnoses: definitions, criteria and explanatory notes for terminology and specimen adequacy. New York: Springer Verlag;1994.
  20. Pinto A, Crum C. Natural history of cervical neoplasia: defining progression and its consequence. Clin Obstet Gynecol 2000;43(2):352-362.
  21. Veldhuijzen NJ, Snijders PJF, Reiss P, Meijer CJLM, can de Wijgert J. Factors affecting transmission of mucosal human papillomavirus. Lancet Infect Dis 2010;10:862-874.
  22. Sun X-W, Kuhn L, Ellerbrock TV Chaisson MA, Bush TJ, Wright TC. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Eng J Med 1997;337:1343-1349.
  23. Minkoff H, Feldman J, DeHovitz J, Landesman S, Burk R. A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Am J Obstet Gynecol 1998;178:982-986.
  24. Ellerbrock TV, Chaisson MA, Bush TJ, Sun X-W, Sawo D, Brudney K, Wright TC. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000;283(8):1031-1037.
  25. Moscicki A-B, Elenberg JH, Crowle-Nowick P, Darragh TM, Xu J, Fahrat S. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents, J Infect Dis. 2004;190;1413-1421.
  26. Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad S et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Nat cancer Instit 2005;97(8): 577-586.
  27. Clifford GM, Goncalves AG, Fransceschi S. Human papillomavirus types among women infected with HIV; a meta-analysis. AIDS 2006;20:2337-2344.
  28. Palefsky JM, Holly EA, Hogeboom CJ, Ralston ML, DaCosta, MM, Botts, R et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquired Immune Def Syndr and Human Retrovirology 1998;17(4):314-319.
  29. Palefsky JM, Holy EA, Ralston, ML, Arthur SP, Jay, N, Berry JM et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J Acquired Immune Def Syndromes and Human Retrovirology 1998:17(4):32-326.
  30. Palefsky JM, Holy EA, Ralston ML, Jay N, Berry JM and Darragh TM. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998; 12:495-503.
  31. Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high risk HIV-negative women. J Natl Cancer Inst 1999;91:226-236.
  32. Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 2001;93:843-849.
  33. Ahdieh L, Klein RS, Burk R, Cu-Urvin S, Schuman P, Duerr A et al. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 2001;184:682-690.
  34. Maiman M. Management of cervical neoplasia in human immunodeficiency virus-infected women. J Natl Cancer Inst 1998;23:43-49.
  35. Robinson WR, Hamilton CA, Michaels SH, Kisinger P. Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus. Am J Obstet Gynecol 2001;184:538-543.
  36. Reimers LL, Sotardi S, Daniel D, Chiu LG, Van Arsdale A, Wieland DL et al. Outcomes after an excisional procedure for cervical intraepithelial neoplasia in HIV-infected women. Gynecol Onc 2010;119:92-97.
  37. Vernon SD, Hart CE, Reeves WC, Icenogle JP. The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription. Virus Res. 1993;27(2):133-145.
  38. Chin-Hong PV, Husnik M, Cranston RD, Colfax G, Buchbinder S, Da Costa M et al. Anal human papillomavirus infection is associated with HIV-acquisition in men who have sex with men. AIDS 2009,23:1135-1142.
  39. Averbach SH, Gravitt PE, Nowak RG, Celentano DD, Dunbar MS, Morrison CS et al. The association between cervical human papillomavirus infection and HIV acquisition among women in Zimbabwe. AIDS 2010;24;1035-1042.
  40. Nowak RG, Gravitt PE, Morrison CS, Grange SJ, Kwok C, Oliver AE et al. Increases in human papillomavirus detection during early HIV infection among women in Zimbabwe. J Infect Dis 2011;203:1182-1191.
  41. Franceschi S, Dal Maso L, Arniani S et al. Risk of cancer other than Kaposi’s sarcoma and non Hodgkin’s lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study. Br J Cancer 1998;78:966.
  42. Serraino D, Carrieri P, Pradier C, Bidoli E, Dorrucci, Ghetti E et al. Risk of invasive cervical cancer among women with, or at risk for, HIV infection. Int J Cancer;1999;82:334-337.
  43. Serraino D, Dal Maso L, La Vecchia C, Franceschi S. Invasive cervical cancer as an AIDS-defining illness in Europe. AIDS 2002;16:781.
  44. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993;269:729.
  45. Massad LS, Riester KA, Anastos KM, Fruchter RG, Palefsky JM et al. Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. J Acq Immune Def Syndr. 1998;21:33-41.
  46. Wright TC Jr, Ellerbrock TV, Chiasson MA et al. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol 1994;84:591.
  47. The American Congress of Obstetricians and Gynecologists. Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 117: Gynecologic care for women with Human Immunodeficiency Virus. 2010:117:1-18.
  48. Final Recommendation Statement: Cervical Cancer: Screening. U.S. Preventive Services Task Force. October 2014. Available at
    http://www.uspreventiveservicestaskforce.org/Page /Document/Recommendation StatementFinal/cervical-cancer-screening
  49. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf. [Section accessed 10/11/15: P-1-P20]
  50. The American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists: Screening for Cervical Cancer. November, 2012.
  51. US Preventive Services Task Force Final Update Summary: Cervical Cancer: Screening. U.S. Preventive Services Task Force. July 2015. http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal /cervical-cancer-screening
  52. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M et al. 2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. 2013, American Society for Colposcopy and Cervical Pathology. J Lower Gen Tract Dis 2013:17(5):S1-S27.
  53. Maiman M, Watts H, Anderson J, Clax P, Merino M, Kendall MA. Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: a randomized trial. Obstet Gynecol 1999;94:954-961.
  54. Maiman M, Fruchter RG, Serur E, Levine PA, Arrastia CD, Sedlis A. Recurrent cervical intraepithelial neoplasia in human immunodeficiency virus-seropositive women. Obstet Gynecol 1993;82:170-174.
  55. Gilles C, Manigart Y, Konopnicki D, Barlow P, Rozenberg S. Management and outcome of cervical intraepithelial neoplasia lesions: a study of matched cases according to HIV status. Gyneco Onc 2005;96:112-118.
  56. Ahdieh-Grant L, Li R, Levine AM, Massad LS, Strickler HD, Minkoff H. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Nat Cancer Inst 2004;96(14):1070-1076.
  57. Minkoff H, Ahdieh L, Massad LS, Anastos K, Watts DH, Melnick S et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 2001;15:2157-2164.
  58. Adler DH, Kakinami L, Moids enyane T, Tshabangu N, Mohapi LDe Bruyn G et al. Increased regression and decreased incidence of human papillomavirus-related cervical lesions among HIV-infected women on HAART. AIDS 2012;26(13):1645-1652.
  59. Konopnicki D, Manigart Y, Gilles C, Barolow P, de Marchin J, Feoli F et al. Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women. J Infect Dis 2013:207;1723-1729.
  60. Blitz S, Baxter J, Raboud J, Walmsley S, Rachlis A, Smaill F et al. Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus. J Infect Dis 2013;208:452-462.
  61. Heard I, Tassie J-M, Kazatchkine MD, Orth G. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS 2002;16:1799-1802.
  62. Delmas M_C, Larsen, C, van Benthem B, Hamers FF, Bergeron C, Poveda J-D et al. Cervical squamous intraepithelial lesions in HIV-infected women: prevalence, incidence and regression. AIDS 2000;14:1775-1784.
  63. Paramsothy P, Jamieson DJ, Heilig CM, Schuman PC, Klein RS Shah KV et al. The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet & Gynecology 2009;113(1):26-31.
  64. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR et al. Cervical Cancer, Version 2.2015. J Natl Compr Canc Netw 2014;13(4):395-404.
  65. Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012;54(7):1026-1034.
  66. Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012;13:487-500.
  67. Bower M, Powles T, Newsom-Davis T, Thirlwell C, Stebbing J, Mandalia S et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 2004;37(5):1563-1565.
  68. Diamond C, Taylor TH, Aboumrad T, Bringman D, Anton-Culver H. Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sexually Transmitted Diseases 2005;32(5):314-320.
  69. Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008;22:1203-1211.
  70. Palefsky JM, Holly EA, Efirdc JT, Da Costa M, Jay Net al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 2005;19:1407-1414.
  71. D’Souza G, Wiley DJ, Li X, Chmiel JS, Margolick JB, Cranston RD et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008;48:491-499.
  72. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008;148:728-736.
  73. Crum-Cianflone NF, Hullsiek KH, Marconi VC, Ganesan A, Weintrob A, Barthel RV et al. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS. 2010;24:535-543.
  74. De Pokomandy A, Rouleau D, Ghattas G, Trottier H, Vezina S, Cote P et al. HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis 2011;52(9);1174-1181.
  75. Van der Snoek EM, van der Ende ME, den Hollander JC, Shutten M, Neumann HA, van Doornum GJ. Use of highly active antiretroviral therapy is associated with lower prevalence of anal intraepithelial neoplastic lesions and lower prevalence of human papillomavirus in HIV-infected men who have sex with men. Sex Transm Dis 2012;39(7):495-500.
  76. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002;35:1127-1134.
  77. Goldstone SE, Kawalek AZ, Huyett JW. Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions. Dis Colon Rectum 2005;48:1042-1054.
  78. Marks DK, Goldstone SE. Electrocautery ablation of high-grade anal squamous intraepithelial lesions in HIV-negative and HIV-positive men who have sex with men. J Acqui Immune Defi Syndr 2012;59(3):259-265.
  79. Richel O, Wieland U, de Vries HJ, Rokmeyer NH, van Noesel C, Potthoff A et al. Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men.Br J Dermatol 2010;163(6):1301.
  80. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML. High-resolution anoscopy targeted surgical destruction of anal highgrade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum. 2008;15:829-837.
  81. Richel O, de Vries HJ, van Noesel CJ et al. Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label randomized controlled trial. Lancet Oncol 2013;14:346.
  82. U.S. National Institutes of Health. Topical or ablative treatment in preventing anal cancer in patients with HIV and anal high-grade squamous Intraepithelial lesions; October 2015. Available at https://clinicaltrials.gov/ ct2/show/NCT02135419.
  83. Beck DE, Jaso RG, Zajac RA. Surgical management of anal condylomata in the HIV-positive patient. Dis Colon Rectum. 1990;33(3):180.
  84. Conley LJ, Ellerbrock TV, Bush TJ, Chiasson MA, Sawo D, Wright TC. HIV-1 infection and risk of vulvovaginal and perianal conylomata acuminate and intraepithelial neoplasia: a prospective cohort study. Lancet 2002;359(9301):108.
  85. Piketty C, Darragh TM, Da Costa M, Bruneval P, Heard I, Kazatchkine MD, Palefsky JM. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med. 2003;138(6):453.
  86. Ciobotaru B, Leiman G, St John T, Hyman N, Ramundo M, Grace C. Prevalence and risk factors for anal cytologic abnormalities and human papillomavirus infection in a rural population of HIV-infected males. Dis Colon Rectum. 2007;50(7):1011.
  87. Massad LS, Silverberg MJ, Springer G, Minkoff H, Hessol N, Palefsky JM et al. Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus. Am J Obstet Gynecol 2004;190:1241- 1248.
  88. Greenspan D, Canchola AJ, MacPhail LA, Cheikh B, Greenspan JS. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 2001;357 (9266):1411-1412.
  89. King MD, Reznik DA, O’Daniels CM, Larsen NJ, Osterhold D, Blumberg HM. Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002;34(5):641-648.
  90. Beachler DC, D”Souza G. Oral HPV infection and head and neck cancers in HIV-infected individuals. Curr Opin Oncol. 2013;25(5):503- 510.
  91. Food and Drug Administration. Product approval-prescribing information [Package insert]. Cervarix [human papillomavirus bivalent (types 16,18) vaccine, recombinant], Glaxo Smith Kline. Silver Spring, MD:US Department of Health and Human Services, Food and Drug Administration; February 2015. Available at http://www.fda.gov/ downloads/BiologicsBloodVaccines/ Vaccines/ApprovedProducts/UC.
  92. Food and Drug Administration. Product approval-prescribing information [Package insert[. Gardasil [human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant, Merck & Co, In. Silver Spring, MD:US Department of Health and Human Services, Food and Drug Administration; April 2015. Available at http://www.fda.gov/downloads/ BiologicsBloodVaccines/Vaccines/ ApprovedProducts/UC.
  93. Food and Drug Administration. Product approval-prescribing information [Package insert]. Gardasil-9 [human papillomavirus 9-valent vaccine, recombinant, Merck & Co, In. Silver Spring, MD:US Department of Health and Human Services, Food and Drug Administration; August 2015. Available at http://www.fda.gov/downloads/ BiologicsBloodVaccines/Vaccines/ ApprovedProducts/UC.
  94. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356;1928-1943.
  95. Future II study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927.
  96. Joura EA, Guilaiano AR, Iverson OE, Bouchar C, Mao CMehlsen J et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015:372:711-723.
  97. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D et al. Efficacy of human papillomavirus (HPV)-16/18 AS04- adjunvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a doubleblind, randomized study in young women. Lancet 2009;374(9686):301-314.
  98. Munoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomized doubleblind trial. Lancet 2009;373:1949-1957.
  99. Guilano AR, Palefsky JM, Goldstone S, Moneira ED, Penny ME, Aranda C et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011;364:401-411.
  100. Levin MJ, Moscicki A-B, Song L-Y, Fenton T, Meye WA, Read JS. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acq Immune Def Syndr 2010;55(2):197- 204.
  101. Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010;202(8):1246-1253.
  102. Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K et al. Safety and immunogenicity of the HPV-16/18 AS04- adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomized placebo-controlled study. Vaccine 2013;31:5745-5753.
  103. Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis. 2013;57(5):735-744.
  104. Centers for Disease Control and Prevention. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports. 2014/63(RR05);1-30
  105. Winer RI, Hughes JP, Feng Q et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354(25):2645-2654.
  106. Manhart LE, Koutsy LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002;29(11):725-735

 
  TOP
© Copyright 2017, Rutgers, The State University of New Jersey, an equal opportunity, affirmative action institution.

Privacy Policy